Liposome News and Research

Latest Liposome News and Research

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Scientists develop new type of carrier that combines photosensitivity and magnetism to fight cancer

Scientists develop new type of carrier that combines photosensitivity and magnetism to fight cancer

CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

Data demonstrates benefits associated with use of EXPAREL in hip, knee replacement patients

Data demonstrates benefits associated with use of EXPAREL in hip, knee replacement patients

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

Janssen granted Priority Review from FDA for YONDELIS (trabectedin) NDA to treat STS patients

Janssen granted Priority Review from FDA for YONDELIS (trabectedin) NDA to treat STS patients

Janssen submits YONDELIS NDA for treatment of advanced soft tissue sarcoma

Janssen submits YONDELIS NDA for treatment of advanced soft tissue sarcoma

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

Liposomes can help prevent bacterial toxins from killing human cells

Liposomes can help prevent bacterial toxins from killing human cells

Scientists develop new system to treat a host of genetic conditions

Scientists develop new system to treat a host of genetic conditions

Encapsula releases 2 new liposome based products

Encapsula releases 2 new liposome based products

Scientists use femtosecond lasers to tackle Parkinson's disease

Scientists use femtosecond lasers to tackle Parkinson's disease

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Celsion acquires all assets of EGEN

Celsion acquires all assets of EGEN

Enhancing vaccine efficiency through encapsulation

Enhancing vaccine efficiency through encapsulation

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion signs definitive asset purchase agreement to acquire EGEN

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Aradigm’s common shares approved for listing on NASDAQ Capital Market

3D capillary device can increase production of high-quality liposomes

3D capillary device can increase production of high-quality liposomes

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014